Antithyroid cancer effects of human neural stem cells expressing therapeutic genes on anaplastic thyroid cancer cells

2019 ◽  
Vol 121 (2) ◽  
pp. 1586-1598
Author(s):  
Hye‐Ji Shin ◽  
Kyung‐A. Hwang ◽  
Ryeo‐Eun Go ◽  
Seung U. Kim ◽  
Kyung‐Chul Choi
Keyword(s):  
Stem Cells ◽  
Thyroid Cancer ◽  
Neural Stem Cells ◽  
Cancer Cells ◽  
Anaplastic Thyroid Cancer ◽  
Human Neural Stem Cells ◽  
Thyroid Cancer Cells ◽  
Therapeutic Genes

scholarly journals Bcl-2-Associated X Protein Is the Main Mediator of Manumycin A-Induced Apoptosis in Anaplastic Thyroid Cancer Cells

2005 ◽  
Vol 90 (6) ◽  
pp. 3583-3591 ◽  
Author(s):  
Jingxuan Pan ◽  
Huizhi Huang ◽  
Lily Sun ◽  
Bingliang Fang ◽  
Sai-Ching Jim Yeung
Keyword(s):  
Thyroid Cancer ◽  
Cancer Cells ◽  
Anaplastic Thyroid Cancer ◽  
X Protein ◽  
Induced Apoptosis ◽  
Thyroid Cancer Cells

Cationic carboxylate and thioacetate ruthenium(ii) complexes: synthesis and cytotoxic activity against anaplastic thyroid cancer cells

2020 ◽  
Vol 49 (24) ◽  
pp. 8375-8388
Author(s):  
Denise Lovison ◽  
Lorenzo Allegri ◽  
Federica Baldan ◽  
Maurizio Ballico ◽  
Giuseppe Damante ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Cytotoxic Activity ◽  
Cancer Cells ◽  
Anaplastic Thyroid Cancer ◽  
Thyroid Cancer Cells

High cytotoxic and antimetastatic activities against anaplastic thyroid cancer are displayed by cationic complexes [RuX(CO)(dppb)(phen)]Y (X = Y = OAc, OPiv, SAc, and NCS; X = Cl and Y = PF6).

Abstract 184: Effects of the magnetic-organic compound Fe(salen) on anaplastic thyroid cancer cells

2017 ◽  
Author(s):  
Shuzo Tamura ◽  
Takashi Oshima ◽  
Mariko Kamiya ◽  
Shinya Amano ◽  
Toru Aoyama ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Organic Compound ◽  
Cancer Cells ◽  
Anaplastic Thyroid Cancer ◽  
Thyroid Cancer Cells

scholarly journals Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance

2019 ◽  
Vol 21 (1) ◽  
pp. 237 ◽  
Author(s):  
Husain Yar Khan ◽  
James Ge ◽  
Misako Nagasaka ◽  
Amro Aboukameel ◽  
Gabriel Mpilla ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Cancer Cells ◽  
Rho Gtpase ◽  
Kinase Inhibitor ◽  
Progression Free Survival ◽  
Anaplastic Thyroid Cancer ◽  
Therapy Resistance ◽  
Molecular Profile ◽  
The Impact ◽  
Thyroid Cancer Cells

Lenvatinib is a multitargeted tyrosine kinase inhibitor (TKI) that shows improved median progression-free survival (PFS) in patients with thyroid carcinomas. However, virtually all patients ultimately progress, indicating the need for a better understanding of the mechanisms of resistance. Here, we examined the molecular profile of anaplastic thyroid cancer cells (8505C) exposed to lenvatinib and found that long-term exposure to lenvatinib caused phenotypic changes. Consistent with change toward mesenchymal morphology, activation of pro-survival signaling, nuclear exporter protein exportin 1 (XPO1) and Rho GTPase effector p21 activated kinases (PAK) was also observed. RNA-seq analysis showed that prolonged lenvatinib treatment caused alterations in numerous cellular pathways and several oncogenes such as CEACAM (carcinoembryonic antigen-related cell adhesion molecule) and NUPR1 (Nuclear protein 1) were also upregulated. Further, we evaluated the impact of XPO1 and PAK4 inhibition in the presence or absence of lenvatinib. Targeted inhibition of XPO1 and PAK4 could sensitize the 8505C cells to lenvatinib. Both XPO1 and PAK4 inhibitors, when combined with lenvatinib, showed superior anti-tumor activity in 8505C sub-cutaneous xenograft. These studies bring forward novel drug combinations to complement lenvatinib for treating anaplastic thyroid cancer. Such combinations may possibly reduce the chances of lenvatinib resistance in thyroid cancer patients.

Sign in / Sign up

Export Citation Format

Share Document